Fresubin 2 kcal Drink: High-calorie medical nutrition in focus

Responsible: ad hoc news B2B & Pro Desk. Reviewed prior to publication on June 13, 2026 at 8:12 AM ET. Details in the imprint.

Fresubin 2 kcal Drink from Fresenius Kabi is a high-calorie, high-protein oral nutritional supplement formulated for medical use in patients with or at risk of disease-related malnutrition. It delivers 2 kcal per milliliter in a 200 ml bottle, providing approximately 400 kcal per serving together with elevated protein content to support nutritional therapy in a compact volume. The ready-to-drink formula is typically used under medical supervision in hospitals, nursing homes, and homecare settings when normal food intake is inadequate or impossible.

What Fresubin 2 kcal Drink is designed to do

Fresubin 2 kcal Drink is part of the clinical nutrition portfolio of Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA that focuses on infusion therapy, clinical nutrition, and related medical devices. According to Fresenius Kabi’s product information, the drink is classified as a food for special medical purposes (FSMP) for the dietary management of patients with or at risk of malnutrition and is generally intended for use under medical supervision. The energy density of 2 kcal/ml aims to help patients reach caloric targets when their appetite or fluid tolerance is reduced, allowing higher energy intake in less volume than standard oral supplements that usually provide around 1 to 1.5 kcal/ml.

The formulation of Fresubin 2 kcal Drink is usually high in protein, often around 20 grams per 200 ml bottle depending on flavor and market variant, which contributes to maintaining or rebuilding lean body mass in patients with increased protein needs. Product documentation states that it provides a balanced mix of macronutrients (protein, fat, carbohydrates) together with vitamins and minerals, offering a nutritionally complete option when consumed in sufficient quantities as part of a care plan. Indications commonly mentioned for similar high-energy oral nutrition supplements include patients with chronic diseases, postoperative recovery, oncology-related weight loss, frailty in older adults, and other conditions associated with reduced oral intake or increased metabolic demand, although the exact indication list can vary by local labeling.

Fresubin 2 kcal Drink is typically offered in multiple flavors to support adherence in long-term use, such as vanilla, chocolate, strawberry, or cappuccino, although exact flavor portfolios differ between countries and regulatory approvals. Packaging is designed for practical handling in clinical environments, with a compact bottle volume that can be consumed directly or via a straw, and the product can often be served chilled to improve palatability for patients who might struggle with rich textures. Many hospitals integrate such oral supplements into standardized nutrition protocols, where dietitians and physicians prescribe defined daily quantities according to the patient’s body weight, disease state, and overall dietary intake.

Fresenius Kabi emphasizes that Fresubin 2 kcal Drink is not intended as a general lifestyle or sports supplement but as a medical nutrition product linked to disease-related malnutrition and prescribed or recommended by healthcare professionals. In practice, this means that usage is often reimbursed by health systems or insurers in many markets when prescribed as part of a clinical nutrition regimen, and instructions for use usually stress that the product should not replace a varied diet in people without medical need. For U.S. readers, availability and labeling of specific Fresubin formulations can differ from those in Europe, because Fresenius has historically marketed some clinical nutrition lines primarily in European and other international markets while offering partly different brands and formulations in the United States.

For Fresenius SE & Co. KGaA, medical nutrition is one component of a broader health care portfolio that also includes pharmaceuticals and services, with Fresenius Kabi active in more than 100 countries and focusing on therapies for chronically and critically ill patients. Shares of Fresenius SE & Co. KGaA (DE0005785604, ticker FRE) last traded on Xetra in Frankfurt; the company does not have a primary listing on the NYSE or Nasdaq.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.